In patients with NSCLC, EGFR-targeted RTK inhibitors, such as gefitinib and erlotinib, have produced objective response rates in about 10% of patients with advanced stage disease and modest improvements in patient survival [70,71,72]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.